Zevaquenabant

Cat. No.:	HY-141411A
CAS No.:	1998760-00-1
Molecular Formula:	$C_{25}H_{21}ClF_3N_5O_2S$
Molecular Weight:	547.98
Target:	Cannabinoid Receptor; NO Synthase
Pathway:	GPCR/G Protein; Neuronal Signaling; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD)[1].
IC_{50} & Target	CB1
In Vitro	Zevaquenabant can simultaneously inhibit CB1 receptors and inducible NOS in peripheral organs[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week-old male C57Bl/6J mice (diet-induced obesity)[1]
Dosage:	3 mg/kg
Administration:	P.o.; for 28 days
Result:	Improved kidney morphology and function in diet-induced obese mice.

REFERENCES

[1]. Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA